ZA201201570B - A method of crystallization of (s)-n-methyl-3-1(1-naphthyloxy)-3-(2-thienyl)propylamine hydrochloride (duloxetine) - Google Patents
A method of crystallization of (s)-n-methyl-3-1(1-naphthyloxy)-3-(2-thienyl)propylamine hydrochloride (duloxetine)Info
- Publication number
- ZA201201570B ZA201201570B ZA2012/01570A ZA201201570A ZA201201570B ZA 201201570 B ZA201201570 B ZA 201201570B ZA 2012/01570 A ZA2012/01570 A ZA 2012/01570A ZA 201201570 A ZA201201570 A ZA 201201570A ZA 201201570 B ZA201201570 B ZA 201201570B
- Authority
- ZA
- South Africa
- Prior art keywords
- duloxetine
- naphthyloxy
- thienyl
- crystallization
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CZ2009-584A CZ304602B6 (en) | 2009-09-02 | 2009-09-02 | Crystallization process of (S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine hydrochloride (duloxetine hydrochloride) |
| PCT/CZ2010/000099 WO2011026449A1 (en) | 2009-09-02 | 2010-09-02 | A method of crystallization of (s)-n-methyl-3-(1-naphthyloxy)-3- (2-thienyl)propylamine hydrochloride (duloxetine) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201201570B true ZA201201570B (en) | 2013-08-28 |
Family
ID=43413356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2012/01570A ZA201201570B (en) | 2009-09-02 | 2012-03-01 | A method of crystallization of (s)-n-methyl-3-1(1-naphthyloxy)-3-(2-thienyl)propylamine hydrochloride (duloxetine) |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP2473497A1 (en) |
| JP (1) | JP2013503823A (en) |
| KR (1) | KR20120047262A (en) |
| CN (1) | CN102482254A (en) |
| BR (1) | BR112012004862A2 (en) |
| CZ (1) | CZ304602B6 (en) |
| EA (1) | EA021528B1 (en) |
| IL (1) | IL218329A0 (en) |
| MX (1) | MX2012002621A (en) |
| WO (1) | WO2011026449A1 (en) |
| ZA (1) | ZA201201570B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103626735A (en) * | 2012-08-28 | 2014-03-12 | 石药集团中奇制药技术（石家庄）有限公司 | Duloxetine hydrochloride crystal form and preparation method thereof |
| CN104478849A (en) * | 2014-02-14 | 2015-04-01 | 广东东阳光药业有限公司 | Method for preparing noradrenaline reuptake dual inhibitor |
| CN106265528A (en) * | 2015-05-12 | 2017-01-04 | 法德生技药品股份有限公司 | The method preparing medicine agglutination body |
| JP2016222628A (en) * | 2015-06-03 | 2016-12-28 | 株式会社トクヤマ | Method for producing duloxetine hydrochloride |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR880007433A (en) | 1986-12-22 | 1988-08-27 | 메리 앤 터커 | 3-aryloxy-3-substituted propanamine |
| US5362886A (en) | 1993-10-12 | 1994-11-08 | Eli Lilly And Company | Asymmetric synthesis |
| DE10212301A1 (en) | 2002-03-20 | 2003-10-02 | Bayer Ag | Process for the preparation of aryl aminopropanols |
| ES2293029T3 (en) | 2002-07-09 | 2008-03-16 | Lonza Ag | PROCESS FOR THE PREPARATION OF BETA-AMINO N-MONOSUSTITUDED ALCOHOLS. |
| GB0410470D0 (en) * | 2004-05-11 | 2004-06-16 | Cipla Ltd | Pharmaceutical compound and polymorphs thereof |
| CZ297560B6 (en) * | 2004-10-26 | 2007-02-07 | Zentiva, A. S. | Process for preparing (S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine hydrochloride (duloxetine) |
| US7534900B2 (en) * | 2005-03-14 | 2009-05-19 | Teva Pharmaceutical Industries Ltd | Process for the purification of duloxetine hydrochloride |
| EP1820800A1 (en) * | 2006-02-17 | 2007-08-22 | KRKA, tovarna zdravil, d.d., Novo mesto | Crystalline forms of duloxetine hydrochloride and processes for their preparation |
| GB0612508D0 (en) * | 2006-06-23 | 2006-08-02 | Arrow Int Ltd | Crystalline duloxetine hydrochloride |
| GB0612509D0 (en) * | 2006-06-23 | 2006-08-02 | Arrow Int Ltd | Crystalline duloxetine hydrochloride |
| CZ300116B6 (en) * | 2006-12-05 | 2009-02-11 | Zentiva, A. S. | Purification process of (S)-N-methyl-3-(1-naphtyloxy)-3-(2-thienyl) propylamine hydrochloride |
| EP2132192B1 (en) * | 2007-03-05 | 2013-04-24 | Lupin Limited | Novel process for preparation of duloxetine hydrochloride |
-
2009
- 2009-09-02 CZ CZ2009-584A patent/CZ304602B6/en not_active IP Right Cessation
-
2010
- 2010-09-02 CN CN2010800392370A patent/CN102482254A/en active Pending
- 2010-09-02 MX MX2012002621A patent/MX2012002621A/en not_active Application Discontinuation
- 2010-09-02 EA EA201290127A patent/EA021528B1/en not_active IP Right Cessation
- 2010-09-02 JP JP2012527196A patent/JP2013503823A/en active Pending
- 2010-09-02 KR KR1020127004225A patent/KR20120047262A/en not_active Application Discontinuation
- 2010-09-02 EP EP10771629A patent/EP2473497A1/en not_active Withdrawn
- 2010-09-02 WO PCT/CZ2010/000099 patent/WO2011026449A1/en active Application Filing
- 2010-09-02 BR BR112012004862A patent/BR112012004862A2/en not_active IP Right Cessation
-
2012
- 2012-02-27 IL IL218329A patent/IL218329A0/en unknown
- 2012-03-01 ZA ZA2012/01570A patent/ZA201201570B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20120047262A (en) | 2012-05-11 |
| JP2013503823A (en) | 2013-02-04 |
| CZ304602B6 (en) | 2014-07-30 |
| EP2473497A1 (en) | 2012-07-11 |
| CZ2009584A3 (en) | 2011-03-09 |
| BR112012004862A2 (en) | 2015-09-08 |
| EA201290127A1 (en) | 2013-02-28 |
| EA021528B1 (en) | 2015-07-30 |
| CN102482254A (en) | 2012-05-30 |
| IL218329A0 (en) | 2012-04-30 |
| MX2012002621A (en) | 2012-07-03 |
| WO2011026449A1 (en) | 2011-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2513434T3 (en) | Cam unit for a constructed camshaft | |
| ZA201203115B (en) | Method for producing a mouthpiece cover of a cigaratte | |
| EP2237574A4 (en) | A method for flushing buffered data of serving gateway | |
| GB2476733A8 (en) | A method of creating map data | |
| IL214023A0 (en) | Crystalline n-{(1-s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride | |
| EP1976844A4 (en) | Improved process for pure duloxetine hydrochloride | |
| AP3169A (en) | A method of improved positioning | |
| HRP20160391T1 (en) | A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate | |
| GB201204945D0 (en) | Adjusting a transducer head for transferring data | |
| ZA201400284B (en) | Method for manufacturing a confectionery shell | |
| EP2328815A4 (en) | Method of forming a pouch | |
| ZA201201570B (en) | A method of crystallization of (s)-n-methyl-3-1(1-naphthyloxy)-3-(2-thienyl)propylamine hydrochloride (duloxetine) | |
| EP2465293A4 (en) | Handover method for reducing the amount of data forwarded to a target node | |
| GB0612508D0 (en) | Crystalline duloxetine hydrochloride | |
| IL191921A0 (en) | A novel process for the preparation of (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine, a duloxetine intermediate | |
| GB0700830D0 (en) | Crystalline duloxetine hydrochloride | |
| GB0612506D0 (en) | Crystalline duloxetine hydrochloride | |
| EP2016066A4 (en) | Process for preparing duloxetine | |
| ZA201108919B (en) | Method for modifying a transfer case for a plurality of outputs | |
| GB0815458D0 (en) | Method of transferring timing information over packet network | |
| WO2008093360A3 (en) | A process for preparation of (s)-(+)-n-methyl-3(1-naphthyloxy)-3(2-thienyl)propylamine hydrochloride | |
| IL195059A0 (en) | Process for preparing duloxetine and intermediates thereof | |
| PL2244188T3 (en) | Method for verifying correct data transfer to a video memory | |
| GB2439575B (en) | A Method of Storing Data | |
| IL191525A0 (en) | Process for the preparation of (s)-(-)-n,n-dimethyl-3-(2-thienyl)- 3-hydroxypropanamine, a duloxetine intermediate |